CA2384439A1 - Vecteurs adenoviraux modifies a utiliser en therapie genique - Google Patents

Vecteurs adenoviraux modifies a utiliser en therapie genique Download PDF

Info

Publication number
CA2384439A1
CA2384439A1 CA002384439A CA2384439A CA2384439A1 CA 2384439 A1 CA2384439 A1 CA 2384439A1 CA 002384439 A CA002384439 A CA 002384439A CA 2384439 A CA2384439 A CA 2384439A CA 2384439 A1 CA2384439 A1 CA 2384439A1
Authority
CA
Canada
Prior art keywords
cells
vector
recombinant
gene
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002384439A
Other languages
English (en)
Inventor
Govert Johan Schouten
Ronald Vogels
Dirk Jan Elbertus Opstelten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202966A external-priority patent/EP1083229A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2384439A1 publication Critical patent/CA2384439A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des moyens et des procédés de génération et de fabrication de vecteurs Ad recombinés qui sont modifiés dans des fonctions E2B et/ou E4. Ces vecteurs comportent de préférence des délétions E1 et/ou E2A. A cette fin, le génome du vecteur est modifié dans des régions du promoteur respectives, de façon que le promoteur soit uniquement actif dans une ligne cellulaire complémentaire adéquate ou suivant un certain signal dans le cas d'un promoteur inductible. Le promoteur modifié est, par ailleurs, inactif dans des conditions normales, et dans des cellules mammaliennes et/ou humaines. Ainsi, les vecteurs qui possèdent ce promoteur modifié dans la région E2B et/ou E4, n'expriment pas la région de transcription respective chez les mammifères et/ou les humains.
CA002384439A 1999-09-10 2000-09-11 Vecteurs adenoviraux modifies a utiliser en therapie genique Abandoned CA2384439A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99202966A EP1083229A1 (fr) 1999-09-10 1999-09-10 Vecteurs adénovirales modifiés pour la thérapie génique
EP99202966.0 1999-09-10
US15364199P 1999-09-13 1999-09-13
US60/153,641 1999-09-13
PCT/NL2000/000640 WO2001020014A1 (fr) 1999-09-10 2000-09-11 Vecteurs adenoviraux modifies a utiliser en therapie genique

Publications (1)

Publication Number Publication Date
CA2384439A1 true CA2384439A1 (fr) 2001-03-22

Family

ID=26153368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384439A Abandoned CA2384439A1 (fr) 1999-09-10 2000-09-11 Vecteurs adenoviraux modifies a utiliser en therapie genique

Country Status (3)

Country Link
AU (1) AU7560500A (fr)
CA (1) CA2384439A1 (fr)
WO (1) WO2001020014A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134325A2 (fr) * 2006-05-15 2007-11-22 Introgen Therapeutics, Inc. Procédés et compositions pour la production de protéines à l'aide de vecteurs adénoviraux
WO2008060357A2 (fr) * 2006-09-29 2008-05-22 Canji, Inc. Procédés de production de polypeptide
EP3945094A1 (fr) * 2020-07-31 2022-02-02 Heinrich-Pette-Institut Adénovirus à réplication déficiente

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE278794T1 (de) * 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
EP0954591A2 (fr) * 1996-05-31 1999-11-10 Baxter International Inc. Vecteur mini-adenoviral
AU5253998A (en) * 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors

Also Published As

Publication number Publication date
AU7560500A (en) 2001-04-17
WO2001020014A1 (fr) 2001-03-22

Similar Documents

Publication Publication Date Title
US6878549B1 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
US8236293B2 (en) Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer
US6413776B1 (en) High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6228646B1 (en) Helper-free, totally defective adenovirus for gene therapy
US7906113B2 (en) Serotype of adenovirus and uses thereof
US20060003451A1 (en) Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
US20090098599A1 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
SK156799A3 (en) Method for the production of non-group c adenoviral vectors
CA2378061A1 (fr) Systemes d'empaquetage pour adenovirus humains de recombinaison a utiliser en therapie genique
CA2318737A1 (fr) Procedes de fabrication de vecteurs pseudo-adenoviraux
US20060246569A1 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2384439A1 (fr) Vecteurs adenoviraux modifies a utiliser en therapie genique
EP1083229A1 (fr) Vecteurs adénovirales modifiés pour la thérapie génique
EP1083228A1 (fr) Vecteurs adénovirales modifiés pour la thérapie génique
US20030077828A1 (en) Methods for highly efficient generation of adenoviral vectors
Seth et al. Advantages and disadvantages of multiple different methods of adenoviral vector construction
CA2371069A1 (fr) Systemes et procedes de transfert d'acide nucleique
US7585498B2 (en) Regulation of adenovirus DNA packaging by IPTG
MXPA99011998A (en) Generation of packaging system for human recombinant adenoviral vectors

Legal Events

Date Code Title Description
FZDE Discontinued